Teva (NYSE: TEVA) director receives 7,242 RSUs vesting in 2027

Rhea-AI Filing Summary

Elstein Amir reported acquisition or exercise transactions in this Form 4 filing.

TEVA PHARMACEUTICAL INDUSTRIES LTD director Amir Elstein received a grant of 7,242 restricted share units. These units were awarded on May 28, 2026 and will vest on May 28, 2027. Each unit represents a contingent right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.

After this grant, Elstein holds 7,242 restricted share units directly. The ordinary shares may be represented by American Depositary Shares, with each ADS currently representing one ordinary share.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Elstein Amir

Role null

Type	Security	Shares	Price	Value
Grant/Award	Restricted Share Units	7,242	$0.00	--

Holdings After Transaction: Restricted Share Units — 7,242 shares (Direct, null)

Footnotes (1)

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

Key Figures

RSUs granted: 7,242 units Grant price: $0.00 per unit Underlying ordinary shares: 7,242 shares +3 more

6 metrics

RSUs granted 7,242 units Restricted share units granted on May 28, 2026

Grant price $0.00 per unit Stock-based compensation award, not an open-market purchase

Underlying ordinary shares 7,242 shares One ordinary share underlying each restricted share unit

Units after transaction 7,242 units Total restricted share units held directly after the grant

Vesting date May 28, 2027 Date when restricted share units vest

ADS ratio 1 ADS : 1 ordinary share Each American Depositary Share currently represents one ordinary share

Key Terms

Restricted Share Units, contingent right, American Depositary Shares, vesting

4 terms

Restricted Share Units financial

"Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share"

Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.

contingent right financial

"represents a contingent right to receive, at settlement, one ordinary share or the cash value"

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share"

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

vesting financial

"Restricted share units were granted on May 28, 2026 and vest on May 28, 2027"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Elstein Amir

(Last) (First) (Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV ISRAEL 6944020

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Share Units	(1)	05/28/2026		A		7,242		(2)	(2)	Ordinary Shares(3)	7,242	$0	7,242	D

Explanation of Responses:

1. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

2. Restricted share units were granted on May 28, 2026 and vest on May 28, 2027.

3. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

	/s/ Dov Bergwerk as attorney-in-fact for Amir Elstein	06/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did Teva (TEVA) director Amir Elstein report in this Form 4?

Director Amir Elstein reported receiving a grant of 7,242 restricted share units. These derivative awards give him contingent rights to ordinary shares or equivalent cash value, reflecting stock-based compensation rather than an open-market share purchase or sale.

How many restricted share units did Amir Elstein receive from Teva (TEVA)?

Amir Elstein received 7,242 restricted share units. Each unit is tied to one underlying ordinary share, giving him potential equity exposure in Teva upon vesting, subject to settlement in shares or an equivalent cash amount at the committee’s discretion.

When do Amir Elstein’s Teva (TEVA) restricted share units vest?

The restricted share units granted to Amir Elstein vest on May 28, 2027. Vesting means that on this date, each unit can settle into one ordinary share of Teva or its cash value, according to the Human Resources and Compensation Committee’s decision.

What does each restricted share unit represent for Teva (TEVA) director Amir Elstein?

Each restricted share unit represents a contingent right to receive one Teva ordinary share or the cash value of one ordinary share. This structure links Elstein’s compensation to the company’s equity performance without an immediate cash outlay or open-market trade.

Are Teva (TEVA) American Depositary Shares linked to these restricted share units?

Yes. The filing notes that Teva’s ordinary shares may be represented by American Depositary Shares. Each ADS currently represents one ordinary share, so vested units settled in shares could correspond to ADSs on a one-for-one basis if so represented.